Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
450 subjects with moderate-severe persistent allergic rhinitis will be enrolled in the trial
and divided into three groups for different treatments. Group A：Subjects with Bencycloquidium
Bromide Nasal Spray, Group B：Subjects with Mometasone Furoate Aqueous Nasal Spray, Group
C：Subjects with Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate
Aqueous Nasal Spray.The main purpose of the trial is to evaluate the efficacy of
Bencycloquidium Bromide Nasal Spray alone or in combination with Mometasone Furoate Aqueous
Nasal Spray in the treatment of moderate-severe persistent allergic rhinitis and rhinorrhea.